Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 2, 2002, Pages 420-426

  Yock, Torunn I ^a   Zietman, Anthony L ^a   Shipley, William U ^a   Thakral, Harjot K ^a   Coen, John J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Durability; Hazard rates; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

ANTIGENS; BIOCHEMISTRY; RADIOLOGY; RADIOTHERAPY;

PROSTATECTOMY SERIES;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CALCULATION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0036803117     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02957-7     Document Type: Article

References (25)

1. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
2. Amling C.L., Blute M.L., Bergstralh E.J., et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer Continued risk of biochemical failure after 5 years . J Urol. 164:2000;101-105.
3. Willett C.G., Zietman A.L., Shipley W.U., et al. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol. 151:1994;1579-1581.
4. American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
5. Zietman A.L., Coen J.J., Dallow K.C., et al. The treatment of prostate cancer by conventional radiation therapy An analysis of long-term outcome . Int J Radiat Oncol Biol Phys. 32:1995;287-292.
6. Freedman G.M., Hanlon A.L., Lee W.R., et al. Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int J Radiat Oncol Biol Phys. 35:1996;243-250.
7. Davis J.W., Kolm P., Wright G.L. Jr, et al. The durability of external beam radiation therapy for prostate cancer Can it be identified? J Urol. 162:(3 Pt 1):1999;758-761.
8. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer A multi-institutional pooled analysis . JAMA. 281:1999;1598-1604.
9. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;447-457.
10. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.
11. Zietman A.L., Tibbs M.K., Dallow K.C., et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 40:1996;159-162.
12. Kavadi V.S., Zagars G.K., Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer Prognostic implications . Int J Radiat Oncol Biol Phys. 30:1994;279-287.
13. Pollack A., Zagars G.K. External beam radiotherapy for stage T1/T2 prostate cancer How does it stack up? Urology. 51:1998;258-264.
14. Zietman A.L., Coen J.J., Shipley W.U., et al. Radical radiation therapy in the management of prostatic adenocarcinoma The initial prostate specific antigen value as a predictor of treatment outcome . J Urol. 151:1994;640-645.
15. Pollack A., Smith L.G., von Eschenbach A.C. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 48:2000;507-512.
16. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
17. Critz F.A., Williams W.H., Holladay C.T., et al. Post-treatment PSA ≤ 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology. 54:1999;968-971.
18. Critz F.A., Levinson A.K., Williams W.H., et al. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol. 161:1999;1199-1203.
19. Bey P., Carrie C., Beckendorf V., et al. Dose escalation with 3D-CRT in prostate cancer French study of dose escalation with conformal 3D radiotherapy in prostate cancer - Preliminary results . Int J Radiat Oncol Biol Phys. 48:2000;513-517.
20. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
21. Sumi M., Ikeda H., Tokuuye K., et al. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma. Int J Radiat Oncol Biol Phys. 48:2000;519-528.
22. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer A multi-institutional update . JAMA. 277:1997;1445-1451.
23. Pilepich M.V., Krall J.M., al-Sarraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma A randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 45:1995;616-623.
24. Corn B.W., Winter K., Pilepich M.V., Radiation Therapy Oncology Group . Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Urology. 54:1999;495-502.
25. Horwitz E.M., Winter K., Hanks G.E., et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 49:2001;947-956.